These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 29676456)
21. The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. Hewamana S; Lin TT; Jenkins C; Burnett AK; Jordan CT; Fegan C; Brennan P; Rowntree C; Pepper C Clin Cancer Res; 2008 Dec; 14(24):8102-11. PubMed ID: 19088025 [TBL] [Abstract][Full Text] [Related]
22. Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro. Panayiotidis P; Ganeshaguru K; Jabbar SA; Hoffbrand AV Br J Haematol; 1993 Nov; 85(3):439-45. PubMed ID: 8136263 [TBL] [Abstract][Full Text] [Related]
23. Interleukin-4 prevents spontaneous in-vitro apoptosis in chronic lymphatic leukaemia but sensitizes B-CLL cells to melphalan cytotoxicity. Pu QQ; Bezwoda WR Br J Haematol; 1997 Aug; 98(2):413-7. PubMed ID: 9266941 [TBL] [Abstract][Full Text] [Related]
24. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Pedersen IM; Kitada S; Leoni LM; Zapata JM; Karras JG; Tsukada N; Kipps TJ; Choi YS; Bennett F; Reed JC Blood; 2002 Sep; 100(5):1795-801. PubMed ID: 12176902 [TBL] [Abstract][Full Text] [Related]
25. Release of clonal block in B cell chronic lymphocytic leukaemia by engagement of co-operative epitopes on CD40. Jacob A; Pound JD; Challa A; Gordon J Leuk Res; 1998 Apr; 22(4):379-82. PubMed ID: 9669843 [TBL] [Abstract][Full Text] [Related]
26. Mimicking the microenvironment in chronic lymphocytic leukaemia - where does the journey go? Asslaber D; Grössinger EM; Girbl T; Hofbauer SW; Egle A; Weiss L; Greil R; Hartmann TN Br J Haematol; 2013 Mar; 160(5):711-4. PubMed ID: 23205585 [No Abstract] [Full Text] [Related]
27. Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles. Plander M; Seegers S; Ugocsai P; Diermeier-Daucher S; Iványi J; Schmitz G; Hofstädter F; Schwarz S; Orsó E; Knüchel R; Brockhoff G Leukemia; 2009 Nov; 23(11):2118-28. PubMed ID: 19657365 [TBL] [Abstract][Full Text] [Related]
28. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Kitada S; Zapata JM; Andreeff M; Reed JC Br J Haematol; 1999 Sep; 106(4):995-1004. PubMed ID: 10520003 [TBL] [Abstract][Full Text] [Related]
29. Effect of anti-APO1 on spontaneous apoptosis of B cells in chronic lymphocytic leukaemia: the role of bcl-2 and interleukin 4. Mainou-Fowler T; Craig VA; Copplestone AJ; Hamon MD; Prentice AG Leuk Lymphoma; 1995 Oct; 19(3-4):301-8. PubMed ID: 8535223 [TBL] [Abstract][Full Text] [Related]
30. Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia. van Attekum MHA; Terpstra S; Slinger E; von Lindern M; Moerland PD; Jongejan A; Kater AP; Eldering E Oncogene; 2017 Jun; 36(26):3651-3660. PubMed ID: 28192408 [TBL] [Abstract][Full Text] [Related]
31. CD40-ligand/interleukin-2 vaccines in chronic lymphocytic leukemia: the impact of vaccine design. Rezvani K Cytotherapy; 2011 Oct; 13(9):1029-30. PubMed ID: 21916777 [No Abstract] [Full Text] [Related]
32. The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1. Larrayoz M; Blakemore SJ; Dobson RC; Blunt MD; Rose-Zerilli MJ; Walewska R; Duncombe A; Oscier D; Koide K; Forconi F; Packham G; Yoshida M; Cragg MS; Strefford JC; Steele AJ Leukemia; 2016 Feb; 30(2):351-60. PubMed ID: 26488112 [TBL] [Abstract][Full Text] [Related]
33. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Wang D; Freeman GJ; Levine H; Ritz J; Robertson MJ Br J Haematol; 1997 May; 97(2):409-17. PubMed ID: 9163608 [TBL] [Abstract][Full Text] [Related]
34. Modeling the chronic lymphocytic leukemia microenvironment in vitro. Crassini K; Shen Y; Mulligan S; Giles Best O Leuk Lymphoma; 2017 Feb; 58(2):266-279. PubMed ID: 27756161 [TBL] [Abstract][Full Text] [Related]
35. Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L. Cols M; Barra CM; He B; Puga I; Xu W; Chiu A; Tam W; Knowles DM; Dillon SR; Leonard JP; Furman RR; Chen K; Cerutti A J Immunol; 2012 Jun; 188(12):6071-83. PubMed ID: 22593611 [TBL] [Abstract][Full Text] [Related]
37. Role of the microenvironment in chronic lymphocytic leukaemia. Caligaris-Cappio F Br J Haematol; 2003 Nov; 123(3):380-8. PubMed ID: 14616995 [No Abstract] [Full Text] [Related]
38. miR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells. Willimott S; Wagner SD J Biol Chem; 2012 Jan; 287(4):2608-17. PubMed ID: 22139839 [TBL] [Abstract][Full Text] [Related]
39. MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment. Crassini K; Shen Y; Stevenson WS; Christopherson R; Ward C; Mulligan SP; Best OG Br J Haematol; 2018 Aug; 182(3):360-372. PubMed ID: 29767411 [TBL] [Abstract][Full Text] [Related]
40. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. Dicker F; Kater AP; Prada CE; Fukuda T; Castro JE; Sun G; Wang JY; Kipps TJ Blood; 2006 Nov; 108(10):3450-7. PubMed ID: 16741250 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]